Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma

Recommendation ID: IPG630/1
Question: Further research on selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma in the form of prospective studies, including randomised controlled trials, should address patient selection, quality-of-life outcomes and overall survival. Patient selection for the research studies should be done by a
multidisciplinary team. The procedure should only be done in specialist centres by clinicians trained and experienced in managing cholangiocarcinoma.
Any explanatory notes (if applicable): Current evidence on the safety of selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma shows that there are well-recognised, serious but rare safety concerns. Evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.

Source guidance details

Comes from guidance: Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma
Number: IPG630
Date issued: October 2018

Is this a recommendation for the use of a technology only in the context of research?	Yes
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	31/10/2018